<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> results when insulin secretion is unable to keep the plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels as per acceptable range </plain></SENT>
<SENT sid="1" pm="."><plain>This leads to <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and its associated microvascular complications such as <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> (diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>), <z:chebi fb="46" ids="15035">retinal</z:chebi> abnormalities (diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo>), and autonomic, sensory, and <z:e sem="disease" ids="C0235025" disease_type="Disease or Syndrome" abbrv="">motor neuropathies</z:e> (<z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e>) and macrovascular disease </plain></SENT>
<SENT sid="2" pm="."><plain>Historically, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is well known as an <z:hpo ids='HP_0003581'>adult-onset</z:hpo> disease; however, lately, the incidence of the disease is reported to be increasing in children </plain></SENT>
<SENT sid="3" pm="."><plain>Despite the wealth of information concerning type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in adults, data unique to the pediatric age group regarding the pathophysiology and therapy for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are limited </plain></SENT>
<SENT sid="4" pm="."><plain>For treatment in pediatric type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:chebi fb="0" ids="6801">metformin</z:chebi> and insulin are the only <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents approved currently </plain></SENT>
<SENT sid="5" pm="."><plain>There are data of use of other oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs including <z:chebi fb="0" ids="5383">glimepiride</z:chebi>, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, and <z:chebi fb="0" ids="5441">glyburide</z:chebi> (in combination with <z:chebi fb="0" ids="6801">metformin</z:chebi>) in pediatric patients; however, formal clinical trials to establish the safety and efficacy have not been conducted </plain></SENT>
<SENT sid="6" pm="."><plain>This review will compare the clinical pharmacology aspects of the oral type 2 diabetic drugs in pediatric and adult populations in order to determine any differences between the two patient groups </plain></SENT>
</text></document>